title: Therapeutic potential of targeting microRNA-10b in established intracranial glioblastoma: first steps toward the clinic.
abstract: MicroRNA-10b (miR-10b) is a unique oncogenic miRNA that is highly expressed in all GBM subtypes, while absent in normal neuroglial cells of the brain. miR-10b inhibition strongly impairs proliferation and survival of cultured glioma cells, including glioma-initiating stem-like cells (GSC). Although several miR-10b targets have been identified previously, the common mechanism conferring the miR-10b-sustained viability of GSC is unknown. Here, we demonstrate that in heterogeneous GSC, miR-10b regulates cell cycle and alternative splicing, often through the non-canonical targeting via 5'UTRs of its target genes, including MBNL1-3, SART3, and RSRC1. We have further assessed the inhibition of miR-10b in intracranial human GSC-derived xenograft and murine GL261 allograft models in athymic and immunocompetent mice. Three delivery routes for the miR-10b antisense oligonucleotide inhibitors (ASO), direct intratumoral injections, continuous osmotic delivery, and systemic intravenous injections, have been explored. In all cases, the treatment with miR-10b ASO led to targets' derepression, and attenuated growth and progression of established intracranial GBM. No significant systemic toxicity was observed upon ASO administration by local or systemic routes. Our results indicate that miR-10b is a promising candidate for the development of targeted therapies against all GBM subtypes.
authors.affiliation: Department of Neurology, Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital Harvard Medical School, Boston, MA, USA.
authors.forename: Nadiya M
authors.initials: NM
authors.lastname: Teplyuk
authors.affiliation: Department of Neurology, Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital Harvard Medical School, Boston, MA, USA.
authors.forename: Erik J
authors.initials: EJ
authors.lastname: Uhlmann
authors.affiliation: Department of Neurology, Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital Harvard Medical School, Boston, MA, USA.
authors.forename: Galina
authors.initials: G
authors.lastname: Gabriely
authors.affiliation: Simons Foundation, New York, NY, USA.
authors.forename: Natalia
authors.initials: N
authors.lastname: Volfovsky
authors.affiliation: Department of Neurology, Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital Harvard Medical School, Boston, MA, USA.
authors.forename: Yang
authors.initials: Y
authors.lastname: Wang
authors.affiliation: Department of Neurology, Massachusetts General Hospital, Boston, MA, USA.
authors.forename: Jian
authors.initials: J
authors.lastname: Teng
authors.affiliation: Regulus Therapeutics Inc., San Diego, CA, USA.
authors.forename: Priya
authors.initials: P
authors.lastname: Karmali
authors.affiliation: Regulus Therapeutics Inc., San Diego, CA, USA.
authors.forename: Eric
authors.initials: E
authors.lastname: Marcusson
authors.affiliation: Department of Neurology, Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital Harvard Medical School, Boston, MA, USA.
authors.forename: Merlene
authors.initials: M
authors.lastname: Peter
authors.affiliation: Department of Neurology, Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital Harvard Medical School, Boston, MA, USA.
authors.forename: Athul
authors.initials: A
authors.lastname: Mohan
authors.affiliation: Department of Neurology, Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital Harvard Medical School, Boston, MA, USA.
authors.forename: Yevgenya
authors.initials: Y
authors.lastname: Kraytsberg
authors.affiliation: Department of Neurology, Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital Harvard Medical School, Boston, MA, USA.
authors.forename: Ron
authors.initials: R
authors.lastname: Cialic
authors.affiliation: Department of Neurosurgery, Brigham and Women's Hospital Harvard Medical School, Boston, MA, USA.
authors.forename: E Antonio
authors.initials: EA
authors.lastname: Chiocca
authors.affiliation: Department of Neurosurgery, Brigham and Women's Hospital Harvard Medical School, Boston, MA, USA.
authors.forename: Jakub
authors.initials: J
authors.lastname: Godlewski
authors.affiliation: Department of Neurology, Massachusetts General Hospital, Boston, MA, USA.
authors.forename: Bakhos
authors.initials: B
authors.lastname: Tannous
authors.affiliation: Department of Neurology, Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital Harvard Medical School, Boston, MA, USA akrichevsky@rics.bwh.harvard.edu.
authors.forename: Anna M
authors.initials: AM
authors.lastname: Krichevsky
mesh_terms: D064591:Allografts; D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D004195:Disease Models, Animal; D005909:Glioblastoma / Q000188:drug therapy*; D064593:Heterografts; D006801:Humans; D051379:Mice; D035683:MicroRNAs / Q000037:antagonists & inhibitors*; D016376:Oligonucleotides, Antisense / Q000008:administration & dosage*; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; C569259:MIRN10 microRNA, mouse; D035683:MicroRNAs; D016376:Oligonucleotides, Antisense
keywords: alternative splicing; brain tumor; microRNA; oligonucleotide therapeutics; stem cells